MabGenesis is a start-up biopharmaceutical company that utilizes years of antibody research from academia to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. They are specialists in antibody medicine, offering a world-class antibody library called MOURA and a high-efficiency monoclonal antibody isolation technique called IMPACT. Through these technologies, MabGenesis can provide high-quality monoclonal antibodies that recognize subtle differences in the three-dimensional structure of membrane proteins, which are difficult to obtain using conventional methods.

This expands research and development opportunities for new drugs in the pharmaceutical industry. MabGenesis's mission is to contribute to the alleviation of symptoms and improvement of quality of life for people and companion animals suffering from diseases through the provision of innovative antibody medicines based on the latest medical information and their unique foundational technology. They focus on disease areas with high unmet medical needs, such as cancer and zoonotic infectious diseases, in the mature market for human antibodies.

Additionally, in the growing field of animal antibody drugs, MabGenesis aims to become an innovator by completing the MOURA antibody library for dogs and cats and acquiring antibodies in various disease areas. The global market for human antibody drugs is predicted to exceed 14 trillion yen in 2020, while the animal antibody drug market is valued at 600 billion yen and represents a new market. MabGenesis is actively seeking partnership opportunities in their business model, including research collaborations, discovery pipelines, and technology licenses.

They are known as specialists in antibody medicine, offering a pharmaceutical solution that harnesses the selective recognition and binding of target molecules (antigens) by antibodies, resulting in various pharmacological effects. The antibody medicine market is expected to surpass 14 trillion yen in 2020, with a shift toward more effective and safe fully human antibodies as the mainstream in the future. At MabGenesis, understanding the structure and mechanisms of antibodies is fundamental to their expertise